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345Abstracts
Premier’s PerspectiveTM database, the largest U.S. 
hospital drug utilization database, hospitalized bipolar
patients discharged between January 1999 and Septem-
ber 2001 were identiﬁed. Psychotropic treatment patterns
and their relationship with diagnoses, illness severity, 
and patient and institution characteristics were analyzed.
RESULTS: Of 36,339 patients (61% female, mean age
39.7 years), 28.9% were depressed, 21.6% manic, 21.0%
mixed, and 28.5% other episodes. Valproate (45.9%) 
and olanzapine (30.2%) were most commonly prescribed
(Lithium, 24.9%). On average, patients received 3.87
psychotropics; 77.1% received 3 and 32.5% received 5.
Only 7.2% received monotherapy. Antipsychotic + mood
stabilizer combinations were used by 58.0%. Mood 
stabilizers or antipsychotics alone combined with other
classes were used by 23.1% and 12.6% of patients,
respectively. Among depressed patients, 79.1% used anti-
depressants versus 25.5% of manic patients. In depressed
patients with psychosis, 74.5% received atypicals versus
42.8% of patients without psychosis. However, 61.5% 
of depressed patients received anxiolytics and 24.5%
received hypnotics. Olanzapine use increased, and risperi-
done, valproate, and lithium use decreased from
1999–2001. Female, greater severity, and depressed/
mixed diagnosis increased pharmacotherapy complexity.
CONCLUSIONS: Pharmacotherapy for hospitalized
bipolar patients is complex. Combinations of 3 psy-
chotropics were dominant treatment regimens.
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OBJECTIVES: The objectives of this study are to estimate
the diffusion curve of atypical antipsychotic agents and
to investigate the inﬂuence of physician mix and supply
on the diffusion cycle. METHODS: Retrospective analy-
sis of Iowa Medicaid pharmacy claims data were done for
the period January 1990 till June 2000 to identify the per-
centage of patients receiving atypical agents in each
county and each month. Antipsychotic agents were iden-
tiﬁed using the National Drug Codes for antipsychotic
agents. Information on physicians practicing in each
county was obtained from the Iowa Physician Database.
To test whether the diffusion cycle follows the S-shaped
curve, a cubic regression model was run where the depen-
dent variable is percentage of patients receiving atypical
agents in each month and the independent variable is
time. The effect of physician factors were tested using
weighted multiple regression analysis where each inde-
pendent variable was interacted with time, time2 and
time3. RESULTS: The number of observations to test the
shape of the diffusion curve is 126 (state aggregate over
sample period) and the number of observations to test the
inﬂuence of physician mix and supply is 12,474 (99 coun-
ties over sample period). The results revealed that time
and time3 were negatively signiﬁcant and time2 was pos-
itively signiﬁcant suggesting that the diffusion curve
resembles the S-shaped curve. Diffusion of atypical agents
accelerated earlier in counties having higher number 
of physicians. Diffusion accelerated faster in counties 
having higher percentage of high network physicians 
and counties having higher percentage of younger physi-
cians. Information available was not sufﬁcient to indicate
that high psychiatrist counties had a faster diffusion of
atypical agents. CONCLUSIONS: Physician mix and
supply factors affected differently at different phases of
the diffusion cycle. Understanding the role of physician
mix and supply on uneven diffusion will help the 
policy makers develop interventions to take care of this
disparity.
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OBJECTIVES: Research has shown that patients with
schizophrenia may respond better to 2nd generation
antipsychotics versus older antipsychotics due to superior
efﬁcacy and safety proﬁles. However, reduced likelihood
of ethnic minorities receiving newer antipsychotics may
be associated with reduced medication adherence and
health service utilization, potentially contributing to poor
response rates. The purpose of this study was to examine
if ethnicity helped predict whether patients with schizo-
phrenia were prescribed 1) haloperidol versus risperidone
or olanzapine, and 2) risperidone versus olanzapine,
when controlling for other factors. METHODS: Texas
Medicaid claims were analyzed for persons, age 21 to 65,
diagnosed with schizophrenia or schizoaffective disorder,
initiating treatment with olanzapine (N = 1875), risperi-
done (N = 982), or haloperidol (N = 726) between
January 1997 and August 1998. The association between
antipsychotic prescribing and ethnicity (African Ameri-
can, Mexican American, or Caucasian) was assessed
using logistic regression. Covariates included other
patient demographics, region, comorbid mental health
conditions, and prior medication and health care resource
use. RESULTS: The results of the haloperidol versus
risperidone or olanzapine analysis indicated that African
Americans were signiﬁcantly less likely than Caucasians
to receive 2nd generation antipsychotics (OR = 0.657;
95% CI: 0.539, 0.801; p < 0.001). Ethnicity was not asso-
ciated with signiﬁcant differences in the use of risperidone
versus olanzapine. CONCLUSIONS: When other factors
were controlled, African Americans were signiﬁcantly less
likely to receive the newer antipsychotics. Among those
who did receive the newer antipsychotics, ethnicity did
not affect medication choice.
